Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Ultragenyx Pharmaceutical Inc. (RARE)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Ultragenyx Pharmaceutical Inc..
Table 2 shows the detailed insider transactions.
This company's CIK number is 1515673.
Total stock buying since 2015: $613,250.
Total stock sales since 2015: $110,275,150.
Total stock option exercises since 2015: $13,175,837.
Table 3. Detailed insider trading at Ultragenyx Pharmaceutical Inc. (RARE)
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2025-06-20 | Sanders Corazon (corsee) D. | Sale | 2,405 | 37.39 | 89,922 |
| 2025-05-05 | Crombez Eric (EVP and Chief Medical Officer) | Sale | 520 | 39.24 | 20,404 |
| 2025-04-21 | Crombez Eric (EVP and Chief Medical Officer) | Sale | 242 | 35.11 | 8,496 |
| 2025-03-06 | Horn Howard (Chief Financial Officer) | Sale | 1,785 | 40.40 | 72,114 |
| 2025-03-03 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 15,103 | 42.10 | 635,836 |
| 2025-03-03 | Parschauer Karah Herdman (EVP and Chief Legal Officer) | Sale | 12,846 | 42.10 | 540,816 |
| 2025-03-03 | Crombez Eric (EVP and Chief Medical Officer) | Sale | 8,945 | 42.10 | 376,584 |
| 2025-03-03 | Pinion John Richard (See Remarks) | Sale | 14,439 | 42.10 | 607,881 |
| 2025-03-03 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 967 | 42.10 | 40,710 |
| 2025-03-03 | Kassberg Thomas Richard (CBO & EVP) | Sale | 6,028 | 42.10 | 253,778 |
| 2025-03-03 | Kakkis Emil D (President & CEO) | Sale | 73,434 | 42.10 | 3,091,571 |
| 2025-02-28 | Kakkis Emil D (President & CEO) | Sale | 25,000 | 42.48 | 1,062,000 |
| 2025-02-27 | Parschauer Karah Herdman (EVP and Chief Legal Officer) | Sale | 2,990 | 42.84 | 128,091 |
| 2024-12-30 | Kakkis Emil D (President & CEO) | Sale | 11,727 | 42.23 | 495,231 |
| 2024-12-10 | Kakkis Emil D (President & CEO) | Sale | 8,273 | 50.00 | 413,650 |
| 2024-10-10 | Horn Howard (Chief Financial Officer) | Sale | 7,465 | 52.76 | 393,853 |
| 2024-09-03 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 91 | 56.19 | 5,113 |
| 2024-09-03 | Kakkis Emil D (President & CEO) | Sale | 20,000 | 55.85 | 1,117,000 |
| 2024-08-06 | Kakkis Emil D (President & CEO) | Sale | 20,000 | 50.17 | 1,003,400 |
| 2024-07-02 | Sanders Corazon (corsee) D. | Sale | 584 | 40.98 | 23,932 |
| 2024-06-12 | Parschauer Karah Herdman (EVP and Chief Legal Officer) | Sale | 9,806 | 45.00 | 441,270 |
| 2024-05-02 | Crombez Eric (EVP and Chief Medical Officer) | Sale | 354 | 43.66 | 15,455 |
| 2024-04-18 | Crombez Eric (EVP and Chief Medical Officer) | Sale | 142 | 44.10 | 6,262 |
| 2024-03-11 | Kassberg Thomas Richard (CBO & EVP) | Sale | 11,509 | 49.93 | 574,644 |
| 2024-03-07 | Fust Matthew K | Sale | 12,195 | 50.87 | 620,396 |
| 2024-03-01 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 4,768 | 53.76 | 256,327 |
| 2024-03-01 | Parschauer Karah Herdman (EVP and Chief Legal Officer) | Sale | 3,756 | 53.76 | 201,922 |
| 2024-03-01 | Crombez Eric (EVP and Chief Medical Officer) | Sale | 1,238 | 53.76 | 66,554 |
| 2024-03-01 | Pinion John Richard (See Remarks) | Sale | 4,173 | 53.76 | 224,340 |
| 2024-03-01 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 341 | 53.76 | 18,332 |
| 2024-03-01 | Kassberg Thomas Richard (CBO & EVP) | Sale | 1,011 | 53.76 | 54,351 |
| 2024-02-07 | Kakkis Emil D (President & CEO) | Sale | 30,000 | 45.00 | 1,350,000 |
| 2023-10-23 | Kassberg Thomas Richard (CBO & EVP) | Sale | 39,878 | 32.78 | 1,307,200 |
| 2023-10-23 | Kassberg Thomas Richard (CBO & EVP) | Option Ex | 39,878 | 6.86 | 273,563 |
| 2023-10-19 | Kakkis Emil D (President & CEO) | Sale | 47,853 | 33.52 | 1,604,032 |
| 2023-10-19 | Kakkis Emil D (President & CEO) | Option Ex | 47,853 | 6.86 | 328,271 |
| 2023-09-07 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 2,163 | 39.67 | 85,806 |
| 2023-09-07 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Option Ex | 2,000 | 21.00 | 42,000 |
| 2023-09-05 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 6,000 | 37.96 | 227,760 |
| 2023-09-01 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 970 | 37.63 | 36,505 |
| 2023-06-30 | Sanders Corazon (corsee) D. (Director) | Sale | 585 | 46.76 | 27,354 |
| 2023-06-19 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 305 | 48.20 | 14,701 |
| 2023-06-08 | Sanders Corazon (corsee) D. (Director) | Sale | 1,485 | 51.65 | 76,700 |
| 2023-05-18 | Pinion John Richard (See Remarks) | Sale | 2,012 | 50.00 | 100,600 |
| 2023-05-09 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Option Ex | 3,000 | 21.00 | 63,000 |
| 2023-05-04 | Parschauer Karah Herdman (EVP and Chief Legal Officer) | Sale | 4,378 | 45.00 | 197,010 |
| 2023-03-01 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 3,664 | 45.25 | 165,796 |
| 2023-03-01 | Parschauer Karah Herdman (EVP and Chief Legal Officer) | Sale | 3,161 | 45.25 | 143,035 |
| 2023-03-01 | Pinion John Richard (See Remarks) | Sale | 3,755 | 45.26 | 169,951 |
| 2023-03-01 | Huang Dennis Karl (See Remarks) | Sale | 389 | 45.65 | 17,757 |
| 2023-03-01 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 100 | 45.65 | 4,565 |
| 2023-03-01 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 3,881 | 45.25 | 175,615 |
| 2023-03-01 | Kassberg Thomas Richard (CBO & EVP) | Sale | 1,968 | 45.27 | 89,091 |
| 2023-02-28 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 639 | 43.40 | 27,732 |
| 2022-12-21 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 2,031 | 43.96 | 89,282 |
| 2022-10-14 | Dier Mardi (CFO & Executive Vice President) | Sale | 1,629 | 40.16 | 65,420 |
| 2022-10-12 | Dier Mardi (CFO & Executive Vice President) | Sale | 3,484 | 38.22 | 133,158 |
| 2022-06-19 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 295 | 54.78 | 16,160 |
| 2022-04-16 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 132 | 84.55 | 11,160 |
| 2022-03-11 | Kassberg Thomas Richard (CBO & EVP) | Sale | 10,281 | 67.01 | 688,929 |
| 2022-03-07 | Parschauer Karah Herdman (EVP and Chief Legal Officer) | Sale | 5,140 | 62.95 | 323,563 |
| 2022-03-04 | Fust Matthew K (Director) | Option Ex | 7,500 | 40.37 | 302,775 |
| 2022-03-03 | Dier Mardi (CFO & Executive Vice President) | Sale | 420 | 64.55 | 27,111 |
| 2022-03-01 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 2,713 | 66.62 | 180,740 |
| 2022-03-01 | Parschauer Karah Herdman (EVP and Chief Legal Officer) | Sale | 2,886 | 66.62 | 192,265 |
| 2022-03-01 | Pinion John Richard (See Remarks) | Sale | 4,498 | 66.62 | 299,656 |
| 2022-03-01 | Huang Dennis Karl (See Remarks) | Sale | 3,234 | 66.62 | 215,449 |
| 2022-03-01 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 843 | 66.62 | 56,160 |
| 2022-03-01 | Dier Mardi (CFO & Executive Vice President) | Sale | 534 | 66.62 | 35,575 |
| 2022-03-01 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 2,821 | 66.62 | 187,935 |
| 2022-03-01 | Kassberg Thomas Richard (CBO & EVP) | Sale | 2,374 | 66.62 | 158,155 |
| 2022-01-30 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 1,657 | 66.30 | 109,859 |
| 2021-10-14 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 303 | 81.14 | 24,585 |
| 2021-10-14 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 310 | 81.14 | 25,153 |
| 2021-10-14 | Pinion John Richard (See Remarks) | Sale | 358 | 81.14 | 29,048 |
| 2021-10-14 | Huang Dennis Karl (EVP & Chief Tech Ops Officer) | Sale | 358 | 81.14 | 29,048 |
| 2021-10-14 | Huizenga Theodore Alan (SVP, Chief Accounting Officer) | Sale | 140 | 81.14 | 11,359 |
| 2021-10-14 | Dier Mardi (CFO & Executive Vice President) | Sale | 3,261 | 81.16 | 264,662 |
| 2021-10-14 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 359 | 81.14 | 29,129 |
| 2021-10-14 | Kassberg Thomas Richard (CBO & EVP) | Sale | 286 | 81.14 | 23,206 |
| 2021-10-12 | Dier Mardi (CFO & Executive Vice President) | Sale | 3,477 | 82.79 | 287,860 |
| 2021-09-30 | Kassberg Thomas Richard (CBO & EVP) | Option Ex | 109,734 | .31 | 34,017 |
| 2021-09-08 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 7,336 | 100.65 | 738,368 |
| 2021-09-08 | Parschauer Karah Herdman (EVP and General Counsel) | Option Ex | 7,336 | 54.50 | 399,812 |
| 2021-09-02 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 2,500 | 100.18 | 250,450 |
| 2021-09-02 | Bedrosian Camille L (EVP and Chief Medical Officer) | Option Ex | 2,500 | 55.00 | 137,500 |
| 2021-09-01 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 2,500 | 100.03 | 250,075 |
| 2021-09-01 | Bedrosian Camille L (EVP and Chief Medical Officer) | Option Ex | 2,500 | 55.00 | 137,500 |
| 2021-07-06 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 375 | 91.53 | 34,323 |
| 2021-06-10 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 1,329 | 100.00 | 132,900 |
| 2021-05-07 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 393 | 113.67 | 44,672 |
| 2021-05-06 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 307 | 113.68 | 34,899 |
| 2021-05-06 | Pinion John Richard (See Remarks) | Sale | 363 | 113.69 | 41,269 |
| 2021-05-06 | Huang Dennis Karl (EVP & Chief Tech Ops Officer) | Sale | 363 | 113.68 | 41,265 |
| 2021-05-06 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 364 | 113.67 | 41,375 |
| 2021-05-06 | Kassberg Thomas Richard (CBO & EVP) | Sale | 363 | 113.69 | 41,269 |
| 2021-05-03 | Kakkis Emil D (President & CEO) | Sale | 30,000 | 107.80 | 3,234,000 |
| 2021-04-20 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 396 | 104.28 | 41,294 |
| 2021-04-15 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 5,000 | 109.09 | 545,450 |
| 2021-04-15 | Bedrosian Camille L (EVP and Chief Medical Officer) | Option Ex | 5,000 | 55.00 | 275,000 |
| 2021-03-08 | Huizenga Theodore Alan (SVP, Controller and PAO) | Sale | 3,000 | 120.69 | 362,070 |
| 2021-03-02 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 707 | 138.16 | 97,679 |
| 2021-03-01 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 2,470 | 138.17 | 341,279 |
| 2021-03-01 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 3,970 | 138.17 | 548,534 |
| 2021-03-01 | Pinion John Richard (See Remarks) | Sale | 6,198 | 138.17 | 856,377 |
| 2021-03-01 | Huang Dennis Karl (EVP & Chief Tech Ops Officer) | Sale | 4,255 | 138.18 | 587,955 |
| 2021-03-01 | Huizenga Theodore Alan (SVP, Controller and PAO) | Sale | 732 | 138.17 | 101,140 |
| 2021-03-01 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 4,543 | 138.18 | 627,751 |
| 2021-03-01 | Kassberg Thomas Richard (CBO & EVP) | Sale | 4,572 | 138.17 | 631,713 |
| 2021-03-01 | Kakkis Emil D (President & CEO) | Sale | 30,000 | 141.80 | 4,254,000 |
| 2021-02-19 | Aliski William (Director) | Sale | 7,500 | 149.01 | 1,117,575 |
| 2021-02-19 | Aliski William (Director) | Option Ex | 7,500 | 97.85 | 733,875 |
| 2021-01-30 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 2,243 | 140.36 | 314,827 |
| 2021-01-15 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 25,000 | 139.18 | 3,479,500 |
| 2021-01-15 | Bedrosian Camille L (EVP and Chief Medical Officer) | Option Ex | 25,000 | 55.00 | 1,375,000 |
| 2021-01-07 | Huizenga Theodore Alan (SVP, Controller and PAO) | Sale | 4,000 | 140.65 | 562,600 |
| 2021-01-07 | Huizenga Theodore Alan (SVP, Controller and PAO) | Option Ex | 4,000 | 21.00 | 84,000 |
| 2021-01-04 | Kakkis Emil D (President & CEO) | Sale | 30,000 | 136.90 | 4,107,000 |
| 2020-11-02 | Kakkis Emil D (President & CEO) | Sale | 30,000 | 96.82 | 2,904,600 |
| 2020-10-30 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 9,903 | 100.12 | 991,488 |
| 2020-10-30 | Parschauer Karah Herdman (EVP and General Counsel) | Option Ex | 9,903 | 54.50 | 539,713 |
| 2020-10-28 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 97 | 100.00 | 9,700 |
| 2020-10-28 | Parschauer Karah Herdman (EVP and General Counsel) | Option Ex | 97 | 54.50 | 5,286 |
| 2020-10-14 | Harris Erik (EVP & Chief Commercial Officer) | Sale | 220 | 88.00 | 19,360 |
| 2020-10-14 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 325 | 88.00 | 28,600 |
| 2020-10-14 | Pinion John Richard (See Remarks) | Sale | 262 | 88.00 | 23,056 |
| 2020-10-14 | Huang Dennis Karl (EVP & Chief Tech Ops Officer) | Sale | 262 | 88.00 | 23,056 |
| 2020-10-14 | Huizenga Theodore Alan (SVP, Controller and PAO) | Sale | 146 | 87.98 | 12,845 |
| 2020-10-14 | Sharp Shalini (EVP, Finance) | Sale | 375 | 87.99 | 32,996 |
| 2020-10-14 | Bedrosian Camille L (EVP and Chief Medical Officer) | Sale | 262 | 88.00 | 23,056 |
| 2020-10-14 | Kassberg Thomas Richard (CBO & EVP) | Sale | 262 | 87.98 | 23,050 |
| 2020-10-12 | Pinion John Richard (See Remarks) | Sale | 2,780 | 94.47 | 262,626 |
| 2020-10-08 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 10,000 | 95.00 | 950,000 |
| 2020-10-08 | Parschauer Karah Herdman (EVP and General Counsel) | Option Ex | 10,000 | 54.50 | 545,000 |
| 2020-10-06 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 10,000 | 90.00 | 900,000 |
| 2020-10-06 | Parschauer Karah Herdman (EVP and General Counsel) | Option Ex | 10,000 | 48.43 | 484,300 |
| 2020-09-23 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 10,000 | 85.00 | 850,000 |
| 2020-09-23 | Parschauer Karah Herdman (EVP and General Counsel) | Option Ex | 10,000 | 48.43 | 484,300 |
| 2020-09-01 | Kakkis Emil D (President & CEO) | Sale | 30,000 | 82.63 | 2,478,900 |
| 2020-08-21 | Aliski William (Director) | Sale | 5,000 | 86.57 | 432,849 |
| 2020-08-21 | Aliski William (Director) | Option Ex | 5,000 | 58.74 | 293,700 |
| 2020-08-17 | Parschauer Karah Herdman (EVP and General Counsel) | Sale | 12,370 | 88.42 | 1,093,693 |
| 2020-08-17 | Parschauer Karah Herdman (EVP and General Counsel) | Option Ex | 10,000 | 54.50 | 545,000 |
| 2020-08-17 | Sharp Shalini (CFO & Executive Vice President) | Sale | 14,378 | 88.38 | 1,270,785 |
| 2020-08-17 | Sharp Shalini (CFO & Executive Vice President) | Option Ex | 11,357 | 62.18 | 706,212 |
| 2020-08-10 | Siegall Clay B (Director) | Sale | 11,346 | 85.01 | 964,523 |
| 2020-08-10 | Siegall Clay B (Director) | Option Ex | 1,596 | 40.37 | 64,430 |
| 2020-08-07 | Siegall Clay B (Director) | Sale | 23,404 | 85.55 | 2,002,212 |
| 2020-08-07 | Siegall Clay B (Director) | Option Ex | 23,404 | 30.68 | 718,151 |
| 2020-07-13 | Kakkis Emil D (President & CEO) | Sale | 40,000 | 85.35 | 3,414,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
of RARE listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Ultragenyx Pharmaceutical Inc. (symbol RARE,
CIK number 1515673) see
the Securities and Exchange Commission (SEC) website.